Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -13.99 | 6.56 | 12.04 | 146.55 | — | 13.06 | 32.00 | 65.83 | — | 11.92 | 25.69 | 19.29 | — | 18.75 | 40.42 | 10.52 | 11.04 | 33.20 | 20.65 | 21.37 | — |
| — | -49.7% | -62.4% | +122.6% | — | +9.5% | +24.6% | +241.3% | — | -36.4% | -36.4% | +83.4% | — | -43.5% | +95.7% | -50.8% | — | +14.5% | +33.7% | -31.6% | — | |
| P/S Ratio | 1.27 | 1.08 | 0.87 | 0.89 | 1.11 | 1.21 | 1.31 | 2.03 | 2.22 | 1.57 | 2.10 | 1.37 | 1.42 | 1.59 | 1.30 | 1.03 | 1.19 | 2.02 | 1.72 | 2.45 | 3.54 |
| — | -10.7% | -33.5% | -56.1% | -50.1% | -22.8% | -37.6% | +48.7% | +56.6% | -1.2% | +61.8% | +32.6% | +18.6% | -21.1% | -24.3% | -57.9% | -66.3% | -40.0% | -30.8% | -18.0% | +88.6% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 11.90 | 16.73 | 24.74 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -33.5% | — | — | |
| P/FCF | 8.48 | 8.14 | 3.74 | 11.71 | 7.15 | 3.80 | 16.14 | 18.16 | 8.83 | 5.98 | — | — | 6.85 | — | 76.73 | 6.36 | 3.78 | — | 7.99 | — | 18.80 |
| — | +114.4% | -76.8% | -35.5% | -19.1% | -36.5% | — | — | +29.0% | — | — | — | +81.3% | — | +860.2% | — | -79.9% | — | — | — | +289.2% | |
| EV / EBITDA | 32.93 | 3.27 | 5.78 | 6.67 | — | 4.65 | 7.79 | 14.04 | 96.24 | 9.03 | 12.80 | 13.80 | — | 9.80 | 8.72 | 4.91 | 11.41 | 9.43 | 7.75 | 9.13 | — |
| — | -29.7% | -25.8% | -52.5% | — | -48.5% | -39.2% | +1.8% | — | -7.8% | +46.8% | +181.0% | — | +3.8% | +12.5% | -46.2% | — | -22.3% | +8.5% | -33.9% | — | |
| EV / EBIT | 10.47 | 3.76 | 7.01 | 13.85 | — | 6.07 | 12.70 | 19.06 | — | — | 11.23 | 12.90 | — | 10.08 | 15.59 | 6.23 | 9.82 | 17.01 | 10.79 | 12.13 | — |
| — | -38.0% | -44.8% | -27.3% | — | — | +13.1% | +47.7% | — | — | -28.0% | +107.1% | — | -40.8% | +44.5% | -48.7% | — | +12.3% | +25.6% | -21.2% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.6% | 79.4% | 76.1% | 78.4% | 77.9% | 77.0% | 76.6% | 75.1% | 79.6% | 73.6% | 74.8% | 73.7% | 73.6% | 72.6% | 72.4% | 73.6% | 72.5% | 69.4% | 71.2% | 71.0% | 68.6% |
| — | +3.1% | -0.7% | +4.5% | -2.2% | +4.5% | +2.4% | +1.9% | +8.1% | +1.4% | +3.3% | +0.1% | +1.7% | +4.6% | +1.8% | +3.6% | +5.6% | +3.3% | +2.9% | +0.5% | -1.0% | |
| Operating Margin | 15.3% | 28.0% | 15.4% | 10.0% | -50.6% | 24.3% | 18.8% | 13.3% | -1.5% | 17.2% | 17.3% | 10.5% | -205.4% | 14.8% | 13.2% | 21.5% | 7.5% | 17.8% | 15.6% | 20.3% | -11.1% |
| — | +15.4% | -18.2% | -24.9% | -3217.1% | +41.0% | +8.8% | +26.7% | +99.3% | +16.8% | +30.8% | -51.4% | -2841.2% | -17.1% | -15.5% | +6.2% | +167.8% | -16.3% | -43.5% | +12.5% | -138.2% | |
| Net Margin | -7.7% | 16.2% | 7.1% | 0.6% | -59.8% | 20.7% | 4.5% | 3.5% | -23.2% | 13.0% | 8.2% | 7.1% | -142.1% | 8.6% | 2.8% | 9.8% | 10.8% | 6.1% | 8.3% | 11.5% | -8.7% |
| — | -21.7% | +58.9% | -82.7% | -157.8% | +59.0% | -45.0% | -49.9% | +83.7% | +50.8% | +186.8% | -27.7% | -1416.5% | +42.3% | -65.8% | -14.5% | +223.9% | -46.8% | -48.8% | +13.4% | -154.7% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 46.2% | 14.7% | 19.7% | -14.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +137.3% | -85.5% | — | — | |
| ROA | -3.8% | 2.1% | 0.9% | 0.1% | -7.5% | 2.5% | 0.6% | 0.4% | -2.9% | 1.7% | 1.1% | 0.9% | -17.1% | 1.0% | 0.3% | 1.2% | 1.3% | 0.8% | 1.2% | 1.4% | -1.1% |
| — | -18.8% | +65.1% | -82.5% | -157.4% | +51.7% | -47.7% | -51.6% | +82.9% | +70.6% | +222.2% | -22.7% | -1442.1% | +28.5% | -71.6% | -18.8% | +219.9% | -47.5% | -19.5% | +57.4% | -140.1% | |
| ROIC | — | — | — | — | — | — | 1607.1% | — | -16.2% | 46.5% | 60.0% | 286.7% | -213.9% | 8.1% | 8.3% | 14.6% | 7.0% | 29.8% | 26.3% | 78.1% | — |
| — | — | — | — | — | — | +2578.2% | — | +92.4% | +475.1% | +623.7% | +1868.6% | -3171.7% | -72.9% | -68.5% | -81.3% | — | -83.7% | -90.3% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.26 | 0.46 | 0.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -77.2% | — | — | |
| Debt / EBITDA | 1.86 | 0.23 | 5.81 | 2.16 | — | 1.87 | 8.58 | 9.93 | 59.58 | 6.81 | 8.68 | 11.76 | — | 7.90 | 7.97 | 5.16 | 11.28 | 5.21 | 0.69 | 1.02 | — |
| — | -87.8% | -32.3% | -78.2% | — | -72.6% | -1.1% | -15.6% | — | -13.7% | +8.9% | +127.8% | — | +51.6% | +1057.3% | +407.7% | — | +183.6% | -63.5% | -73.1% | — | |
| Current Ratio | 0.59 | 0.86 | 0.71 | 0.62 | 0.59 | 0.63 | 0.60 | 0.58 | 0.58 | 0.61 | 0.52 | 0.49 | 0.45 | 0.54 | 0.52 | 0.56 | 0.49 | 0.47 | 0.66 | 0.59 | 0.75 |
| — | +35.8% | +18.3% | +8.3% | +2.2% | +3.4% | +14.9% | +18.0% | +28.3% | +14.3% | -0.2% | -13.2% | -8.2% | +13.5% | -20.2% | -5.1% | -34.1% | -37.2% | -10.7% | -5.3% | -33.8% | |
| Quick Ratio | 0.57 | 0.82 | 0.69 | 0.60 | 0.57 | 0.60 | 0.57 | 0.54 | 0.55 | 0.57 | 0.49 | 0.45 | 0.42 | 0.48 | 0.48 | 0.51 | 0.45 | 0.43 | 0.60 | 0.54 | 0.71 |
| — | +38.1% | +21.3% | +11.3% | +4.1% | +4.8% | +17.1% | +20.8% | +32.3% | +19.2% | +1.5% | -12.8% | -7.4% | +10.5% | -20.3% | -4.0% | -36.2% | -39.0% | -13.1% | -10.2% | -34.3% | |
| Interest Coverage | -0.13 | 5.01 | 2.87 | 1.15 | -8.61 | 3.20 | 2.04 | 2.08 | -0.13 | -3.40 | 5.47 | 4.10 | -95.62 | 3.27 | 1.74 | 3.60 | 2.08 | 2.75 | 4.25 | 4.78 | -1.95 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CCEL stock.
Cryo-Cell International, Inc.'s current P/E is -14.0x. The average P/E over the last 3 quarters is 55.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cryo-Cell International, Inc.'s current operating margin is 15.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cryo-Cell International, Inc.'s business trajectory between earnings reports.